ERAS
Erasca Inc

523
Loading...
Loading...
News
all
press releases
Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment
Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment PR Newswire VANCOUVER, BC, Dec. 26, 2024 USA News...
PR Newswire·9mo ago
News Placeholder
More News
News Placeholder
Erasca Inc. Poised for Growth: Buy Rating Maintained Amidst Promising Trial Updates and Solid Financials
Chris Shibutani, an analyst from Goldman Sachs, maintained the Buy rating on Erasca (ERAS Research Report). The associated price target was lower...
TipRanks Financial Blog·1y ago
News Placeholder
Erasca (NASDAQ:ERAS) PT Raised to $7.00
Erasca (NASDAQ:ERAS - Free Report) had its target price hoisted by The Goldman Sachs Group from $6.00 to $7.00 in a research report sent to investors on Tuesday morning, Benzinga reports. The...
Ticker Report·1y ago
News Placeholder
Erasca's Promising Naporafenib Data and Financial Stability Merit a Buy Rating
Analyst Graig Suvannavejh from Mizuho Securities maintained a Buy rating on Erasca (ERAS Research Report) and keeping the price target at $7.00...
TipRanks Financial Blog·1y ago
News Placeholder
HC Wainwright Reiterates "Buy" Rating for Erasca (NASDAQ:ERAS)
HC Wainwright restated their buy rating on shares of Erasca (NASDAQ:ERAS - Free Report) in a report issued on Thursday, Benzinga reports. HC Wainwright currently has a $8.00 price objective on the...
Ticker Report·2y ago
News Placeholder
Erasca, Inc. (ERAS) R&D Update Call and Q4 2023 Earnings Call Transcript
Erasca, Inc. (ERAS) R&D Update Call and Q4 2023 Earnings Call Transcript...
SeekingAlpha·2y ago
News Placeholder
Erasca, Inc. (ERAS) R&D Update Call and Q4 2023 Earnings Call Transcript
Erasca, Inc. (ERAS) R&D Update Call and Q4 2023 Earnings Call Transcript...
Seeking Alpha: Transcripts·2y ago
News Placeholder
Erasca Inc (ERAS) Aligns with EPS Projections, Reveals Robust Balance Sheet and Key Clinical ...
Insights into Erasca Inc's Q4 and Full Year 2023 Financial and Operational PerformanceRelated Stocks: ERAS...
GuruFocus·2y ago
News Placeholder
Erasca's Strong Clinical Data and Enhanced Financial Position Support Buy Rating
In a report released today, Naureen Quibria from Capital One Financial reiterated a Buy rating on Erasca (ERAS Research Report), with a price tar...
TipRanks Financial Blog·2y ago
News Placeholder
Erasca Announces $45 Million Oversubscribed Private Placement Financing
Funding from new and existing investors extends anticipated cash runway into H2 2026SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS) ( Erasca ), a clinical-stage precision...
Globe Newswire·2y ago

Latest ERAS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.